Skip to content

13F-HR filed by Stonepine Capital Management, LLC

Stonepine Capital Management, LLC filed this 13F-HR for the quarter ended 2018-09-30, filed 2018-11-13, with 31 holding rows worth $159,157,000.

Accession
0001567619-18-005813
Filed
2018-11-13
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q3 2018

A holdings report, 31 entries on the cover page, a total value of $159,157,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $159,157,000 with VALUE read as thousands by filing date, 13F file number 028-17175. A later restatement replaced it, so the quarter does not use it. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
APOLLO ENDOSURGERY INC03767D108COM2,577,996$18,484,000thousands by filing date
AMARIN CORP PLC023111206SPONS ADR NEW1,130,568$18,394,000thousands by filing date
BIOSPECIFICS TECHNOLOGIES090931106COM285,259$16,685,000thousands by filing date
BIODELIVERY SCIENCES INTL IN09060J106COM4,311,103$12,071,000thousands by filing date
CTI BIOPHARMA CORP12648L601COM4,145,459$8,954,000thousands by filing date
MELINTA THERAPEUTICS INC58549G100COM1,958,595$7,736,000thousands by filing date
VANDA PHARMACEUTICALS INC921659108COM324,600$7,450,000thousands by filing date
VIVEVE MED INC92852W204COM NEW2,599,711$6,967,000thousands by filing date
CUMBERLAND PHARMACEUTICALS I230770109COM1,218,401$6,957,000thousands by filing date
ALIMERA SCIENCES INC016259103COM6,987,856$6,848,000thousands by filing date
OPHTHOTECH CORP683745103COM2,324,782$5,486,000thousands by filing date
NOVELION THERAPEUTICS INC67001K202COM NEW1,728,887$5,118,000thousands by filing date
OXFORD IMMUNOTEC GLOBAL PLCG6855A103ORD SHS225,877$3,666,000thousands by filing date
CORREVIO PHARMA CORP22026V105COM898,157$3,611,000thousands by filing date
OPIANT PHARMACEUTICALS INC683750103COM185,887$3,320,000thousands by filing date
FOAMIX PHARMACEUTICALS LTDM46135105SHS551,078$3,158,000thousands by filing date
KALVISTA PHARMACEUTICALS INC483497103COM138,100$3,053,000thousands by filing date
CIDARA THERAPEUTICS INC COM NEW171757107Stock656,148$2,887,000thousands by filing date
HTG MOLECULAR DIAGNOSTICS IN40434H104COM535,590$2,705,000thousands by filing date
ALPHATEC HLDGS INC02081G201COM NEW751,756$2,533,000thousands by filing date
SPERO THERAPEUTICS INC84833T103COM226,444$2,380,000thousands by filing date
MOLECULAR TEMPLATES INC608550109COM378,295$2,039,000thousands by filing date
ALDEYRA THERAPEUTICS INC01438T106COM145,000$2,001,000thousands by filing date
CATABASIS PHARMACEUTICALS IN14875P107COM2,166,154$1,733,000thousands by filing date
XENON PHARMACEUTICALS INC COM98420N105Stock100,000$1,320,000thousands by filing date
NEOS THERAPEUTICS INC64052L106COM227,919$1,105,000thousands by filing date
SPRING BK PHARMACEUTICALS IN849431101COM71,050$856,000thousands by filing date
CANCER GENETICS INC.13739u104COM614,411$639,000thousands by filing date
SCYNEXIS INC COM NEW811292101Common Stock448,777$539,000thousands by filing date
SENSUS HEALTHCARE INC81728J109COM37,858$317,000thousands by filing date
DOVA PHARMACEUTICALS INC25985T102COM6,900$145,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001567619-18-005813this filing2018-11-13acceptance time not in the bulk data set
13F-HR/A 0001567619-18-007015 base2018-11-28acceptance time not in the bulk data set